DK2146742T3 - Cellelinjer, sammensætninger omfattende disse til behandling af melanomer, fremgangsmåder til at fremstille sammensætningerne og behandlingsmetoder - Google Patents

Cellelinjer, sammensætninger omfattende disse til behandling af melanomer, fremgangsmåder til at fremstille sammensætningerne og behandlingsmetoder

Info

Publication number
DK2146742T3
DK2146742T3 DK08737810.5T DK08737810T DK2146742T3 DK 2146742 T3 DK2146742 T3 DK 2146742T3 DK 08737810 T DK08737810 T DK 08737810T DK 2146742 T3 DK2146742 T3 DK 2146742T3
Authority
DK
Denmark
Prior art keywords
compositions
treatment
methods
melanomas
preparing
Prior art date
Application number
DK08737810.5T
Other languages
Danish (da)
English (en)
Inventor
Jose Mordoh
Maria Marcela Barrio
Euw Erika Maria Von
Original Assignee
Consejo Nac Invest Cient Tec
Fundacion Sales
Inisbiotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nac Invest Cient Tec, Fundacion Sales, Inisbiotech Llc filed Critical Consejo Nac Invest Cient Tec
Application granted granted Critical
Publication of DK2146742T3 publication Critical patent/DK2146742T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK08737810.5T 2007-04-11 2008-04-11 Cellelinjer, sammensætninger omfattende disse til behandling af melanomer, fremgangsmåder til at fremstille sammensætningerne og behandlingsmetoder DK2146742T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ARP070101520A AR060424A1 (es) 2007-04-11 2007-04-11 Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
PCT/IB2008/051385 WO2008126039A2 (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods

Publications (1)

Publication Number Publication Date
DK2146742T3 true DK2146742T3 (da) 2012-10-22

Family

ID=39590605

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08737810.5T DK2146742T3 (da) 2007-04-11 2008-04-11 Cellelinjer, sammensætninger omfattende disse til behandling af melanomer, fremgangsmåder til at fremstille sammensætningerne og behandlingsmetoder

Country Status (17)

Country Link
US (1) US8501168B2 (cg-RX-API-DMAC7.html)
EP (1) EP2146742B1 (cg-RX-API-DMAC7.html)
JP (1) JP5762738B2 (cg-RX-API-DMAC7.html)
KR (1) KR101502518B1 (cg-RX-API-DMAC7.html)
CN (1) CN101861163B (cg-RX-API-DMAC7.html)
AR (1) AR060424A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008238909B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0809767B1 (cg-RX-API-DMAC7.html)
CA (1) CA2683629C (cg-RX-API-DMAC7.html)
CO (1) CO6260100A2 (cg-RX-API-DMAC7.html)
DK (1) DK2146742T3 (cg-RX-API-DMAC7.html)
ES (1) ES2390130T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009010927A (cg-RX-API-DMAC7.html)
NZ (1) NZ580533A (cg-RX-API-DMAC7.html)
RU (1) RU2484134C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008126039A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200907240B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6077735B2 (ja) * 2011-06-08 2017-02-08 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
SG11201401631VA (en) 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine with gamma interferon
JP6077757B2 (ja) * 2012-04-17 2017-02-08 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
JP5921386B2 (ja) * 2012-08-27 2016-05-24 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
CN103146641B (zh) * 2013-02-06 2015-03-25 云南中科灵长类生物医学重点实验室 多能干细胞的传代方法及其用途
CN104990781B (zh) * 2015-06-29 2018-02-16 中国医学科学院皮肤病研究所 黑素细胞免疫组化苏木素—甲苯胺蓝双重复染法
AU2020395765A1 (en) 2019-12-03 2022-06-16 Neuvogen, Inc. Tumor cell vaccines
RU2755233C1 (ru) * 2021-01-11 2021-09-14 Сергей Анатольевич Яргунин Способ лечения меланомы кожи IIb-IIc стадий
CN115074328B (zh) * 2022-06-21 2025-02-07 中国人民解放军空军军医大学 一种用于治疗黑素瘤的细胞株及其多效价全细胞疫苗与使用方法
WO2025224605A1 (en) 2024-04-23 2025-10-30 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Sequential administration of anti-melanoma vaccine and anti-pd-1 monoclonal antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882654A (en) * 1989-11-03 1999-03-16 Morton; Donald L. Polyvalent melanoma vaccine
KR20000022445A (ko) * 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
AU3889997A (en) * 1996-08-16 1998-03-06 Johns Hopkins University School Of Medicine, The Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US7988963B1 (en) * 1999-10-15 2011-08-02 Baylor Research Institute Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses
WO2001028583A2 (en) * 1999-10-18 2001-04-26 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
WO2001048154A1 (en) * 1999-12-28 2001-07-05 Toyoshima, Kumao Maturation-promoting agent for immature dendritic cells
EP1326961B1 (en) * 2000-09-15 2007-08-22 Ortho-McNeil Pharmaceutical, Inc. Compositions and methods for inducing specific cytolytic t cell responses
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
CA2440229A1 (en) * 2001-03-09 2002-09-19 Baylor Research Institute Method of treating malignancies through induction of blood immune responses
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EP1451305A4 (en) * 2001-11-07 2005-10-05 Mannkind Corp EPITOPE SYNCHRONIZATION IN CELLS THAT HAVE ANTIGENS
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
EP1623011B1 (en) * 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
JP5021309B2 (ja) * 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
RU2262941C2 (ru) 2004-01-05 2005-10-27 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ иммунотерапии злокачественных опухолей головного мозга
EP1740946B1 (en) * 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
CA2565874C (en) * 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
RU2283129C1 (ru) 2004-12-24 2006-09-10 Сергей Викторович Луценко Белковопептидный противоопухолевый композит, клеточный препарат, активированный этим композитом, и способ профилактики или лечения опухолей

Also Published As

Publication number Publication date
KR101502518B1 (ko) 2015-03-13
US20100183683A1 (en) 2010-07-22
JP5762738B2 (ja) 2015-08-12
MX2009010927A (es) 2010-02-11
WO2008126039A3 (en) 2008-12-11
CA2683629A1 (en) 2008-10-23
EP2146742B1 (en) 2012-07-11
JP2010523141A (ja) 2010-07-15
RU2484134C2 (ru) 2013-06-10
ES2390130T3 (es) 2012-11-06
BRPI0809767A2 (pt) 2014-09-23
AR060424A1 (es) 2008-06-18
US8501168B2 (en) 2013-08-06
ZA200907240B (en) 2010-07-28
BRPI0809767B1 (pt) 2022-04-12
WO2008126039A2 (en) 2008-10-23
CN101861163A (zh) 2010-10-13
RU2009141593A (ru) 2011-05-20
NZ580533A (en) 2012-08-31
CO6260100A2 (es) 2011-03-22
CN101861163B (zh) 2013-06-12
AU2008238909A1 (en) 2008-10-23
CA2683629C (en) 2016-06-21
KR20090129501A (ko) 2009-12-16
EP2146742A2 (en) 2010-01-27
AU2008238909B2 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
DK2010501T3 (da) Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse
DK3461503T3 (da) Fremgangsmåder til indgivelse af tetrahydrobiopterin, associerede sammensætninger og målingsfremgangsmåder
DK2240155T3 (da) Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
DK2331109T3 (da) Fremgangsmåder og sammensætninger til behandling af knogledefekter med placentale cellepopulationer
DK2209375T3 (da) Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
DK2101819T3 (da) Fremgangsmåder, sammensætninger og kits til behandling af smerte og pruritis
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK2137537T3 (da) Sammensætninger og anvendelser til behandling af multipel sklerose
DK2147315T3 (da) Diabetesrelaterede biomarkører og fremgangsmåder til anvendelse deraf
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
DK3121280T3 (da) Antisense-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2069352T3 (da) Bestemte kemiske enheder, sammensætninger og fremgangsmåder
DK2894165T5 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2252342T3 (da) Indretninger og fremgangsmåder til behandling af skadet væv
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
PL3354276T3 (pl) Kompozycje do leczenia zapalenia przewodu pokarmowego
BRPI0809573A8 (pt) composição, e, método
DK2220116T3 (da) Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza
DK2195548T3 (da) Leje, og fremgangsmåde og håndtering af lejet
DK2134663T3 (da) Beskyttelseslag på højtemperaturudholdende chromoxiddannende substrater, og fremgangsmåde til fremstilling deraf